If your estate plan was created before the DNA testing era—or hasn't been updated to account for these new realities—now is ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a bankruptcy ...

New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase the bankrupt genetic testing firm 23andMe in a $256 million deal that could include millions of Americans' ...

New York and other states filed a lawsuit seeking to block 23andMe, the bankrupt genetic testing firm, from selling millions of Americans' genetic data to the highest bidder. A total of 28 state ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...

The Federal Trade Commission is reportedly investigating various direct-to-consumer genetic testing companies, including market giants 23andMe and Ancestry.com, over concerns related to data sharing ...

The Food and Drug Administration has issued a severe warning to DIY DNA testing firm 23andMe, telling the company to stop advertising its at-home genetic testing kit that the feds say is misleading, ...